HIV-1 protease-substrate coevolution in nelfinavir resistance by Kolli, Madhavi et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Biochemistry and Molecular Pharmacology 
Publications and Presentations Biochemistry and Molecular Pharmacology 
2014-07-01 
HIV-1 protease-substrate coevolution in nelfinavir resistance 
Madhavi Kolli 
University of Massachusetts Medical School Worcester 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/bmp_pp 
 Part of the Biochemistry Commons, Immunology and Infectious Disease Commons, Molecular Biology 
Commons, Pharmacology Commons, and the Virology Commons 
Repository Citation 
Kolli M, Ozen A, Yilmaz NK, Schiffer CA. (2014). HIV-1 protease-substrate coevolution in nelfinavir 
resistance. Biochemistry and Molecular Pharmacology Publications and Presentations. https://doi.org/
10.1128/JVI.00266-14. Retrieved from https://escholarship.umassmed.edu/bmp_pp/205 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Biochemistry and 
Molecular Pharmacology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
HIV-1 Protease-Substrate Coevolution in Nelfinavir Resistance
Madhavi Kolli, Ays¸egül O¨zen, Nese Kurt-Yilmaz, Celia A. Schiffer
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT
Resistance to various human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) challenges the effectiveness of
therapies in treating HIV-1-infected individuals and AIDS patients. The virus accumulates mutations within the protease (PR)
that render the PIs less potent. Occasionally, Gag sequences also coevolve with mutations at PR cleavage sites contributing to
drug resistance. In this study, we investigated the structural basis of coevolution of the p1-p6 cleavage site with the nelfinavir
(NFV) resistance D30N/N88D protease mutations by determining crystal structures of wild-type and NFV-resistant HIV-1 pro-
tease in complex with p1-p6 substrate peptide variants with L449F and/or S451N. Alterations of residue 30’s interaction with the
substrate are compensated by the coevolving L449F and S451N cleavage site mutations. This interdependency in the PR–p1-p6
interactions enhances intermolecular contacts and reinforces the overall fit of the substrate within the substrate envelope, likely
enabling coevolution to sustain substrate recognition and cleavage in the presence of PR resistance mutations.
IMPORTANCE
Resistance to human immunodeficiency virus type 1 (HIV-1) protease inhibitors challenges the effectiveness of therapies in
treating HIV-1-infected individuals and AIDS patients. Mutations in HIV-1 protease selected under the pressure of protease in-
hibitors render the inhibitors less potent. Occasionally, Gag sequences also mutate and coevolve with protease, contributing to
maintenance of viral fitness and to drug resistance. In this study, we investigated the structural basis of coevolution at the Gag
p1-p6 cleavage site with the nelfinavir (NFV) resistance D30N/N88D protease mutations. Our structural analysis reveals the in-
terdependency of protease-substrate interactions and how coevolutionmay restore substrate recognition and cleavage in the
presence of protease drug resistance mutations.
Human immunodeficiency virus type 1 (HIV-1) protease (PR)plays an essential role in the viral life cycle by processing Gag
and GagProPol viral polyproteins, resulting in a mature virus.
Therefore, nine FDA-approved protease inhibitors (PIs) target
PR. PIs are an integral component of highly active antiretroviral
therapy (HAART) (1–3), which also includes reverse transcriptase
inhibitors and, more recently, integrase inhibitors. HAART has
significantly improved the prognosis for HIV-1-infected individ-
uals. Nevertheless, the development of resistance is a major cause
for antiretroviral therapy failure.
Evolution of PI resistance occurs due to a combination of fac-
tors: the lack of a proofreading mechanism of the viral reverse
transcriptase, a high viral replication rate, and selective pressure of
PIs. Mutations occur within the active/substrate binding site of
the PR (4) and compromise inhibitor potency. These mutations
lower the efficacy of the PIs by several orders of magnitude yet
allow the PR to process its substrates, Gag and GagProPol. Resis-
tance thus reflects a change in molecular recognition by the pro-
tease where a balance is maintained between (i) substrate recog-
nition and cleavage and (ii) inhibition by PIs.
HIV-1 Gag processing is a highly regulated and ordered pro-
cess that is essential for the production of mature virions, where
HIV-1 PR recognizes and cleaves 10 specific sites within Gag (5–
7). The sites recognized by the PR are nonhomologous and asym-
metric, but they occupy a conserved volume within the active site
of the PR (8). This volume forms the basis for PR-substrate rec-
ognition, and we previously defined this conserved volume as the
“substrate envelope.” PIs that protrude beyond the substrate en-
velope are susceptible to resistance (9).
PI-resistant viruses accumulate mutations in both the viral PR
and its substrates, Gag and GagProPol (10–12). While some of
these mutations may compensate for loss of viral fitness and im-
prove efficiency of Gag processing by the resistant PR (11, 13), we
previously found that they may also directly modulate drug resis-
tance (14). Frequently, thesemutations arise within theGag cleav-
age sites, particularly theNC-p1 and p1-p6 sites (15–18). Cleavage
site mutations have been specifically associated with several major
protease resistance mutations (14, 16, 17), suggesting that as the
virus evolves resistance to protease inhibitors with prolonged pro-
tease inhibitor therapy, evolution of cleavage sites could be a fairly
frequent mechanism for maintaining viral fitness.
Previously, we reported that the p1-p6 cleavage site coevolves
with the D30N/N88D PRmutations (14, 15) in HIV-1 subtype B.
The D30N mutation at the PR active site arises specifically in re-
sponse to nelfinavir (NFV) inhibition, both in viral cultures and in
patients being treated with NFV, and is often accompanied by the
N88D secondarymutation, causing severe resistance toNFV (19).
Our inhibitor-bound co-crystal structures revealed that theN88D
secondary mutation interacts with residue 30 to orient the side
chain away from the active site (20) and thereby disrupts the in-
teraction between residue 30 and the inhibitor. This effect is
even more pronounced in subtype AE, where N88S pulls D30
out of the active site (21). We also showed that D30 not only is
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key for inhibitor binding but also is essential for recognition of
the p1-p6 cleavage site (8, 15, 22). Consequently, the D30N
mutation, which lowers affinity for NFV (23), also likely com-
promises p1-p6 recognition, leading to coevolution of this
cleavage site (15). Such p1-p6 cleavage site mutations com-
monly observed with D30N/N88D PR are L449F, S451N, and
P453L (14), and they may help restoring the fit of the substrate
in the consensus substrate envelope (24). Mutations are ob-
served at either Gag 449 or 451, but simultaneous occurrence of
both mutations is infrequent (15).
The current study focused on elucidating the structural ratio-
nale for the coevolution of the p1-p6 cleavage site with the NFV-
resistant D30N/N88D HIV-1 protease. We determined crystal
structures of wild-type (WT) and D30N/N88D HIV-1 proteases
in complex with four p1-p6 substrate variants, L449F, S451N,
L449F/S415N, and wild type. (The double mutant substrate,
L449F/S415N, was included to elucidate its infrequent occur-
rence.) Structural analyses of PR and substrate complexes showed
tighter packing around coevolved substrates and an interdepen-
dency of interactions between the PR and the p1-p6 substrate. The
coevolved p1-p6 substrates fit better within the substrate envelope
in the NFV-resistant PR complexes, as we have previously ob-
served with the coevolved NC-p1 (13).
MATERIALS AND METHODS
Nomenclature.HIV-1 protease (WTorD30N/N88D) and the p1-p6 sub-
strate variants (WT, L449F, S451N, and L449F/S451N) in the PR-sub-
strate complexes are distinguished as subscripts. For example, WT pro-
tease in complex withWT p1-p6 is denoted PRWT–p1-p6WT, and mutant
protease in complex with the S451N mutation in p1-p6 is denoted
PRD30N/N88D–p1-p6S451N. The twomonomers of the protease are denoted
a and b.
Substrate peptides.Decameric peptides corresponding to the p1-p6
processing site within the Gag polyprotein (amino acids 444 to 453)
and its variants were purchased from Quality Controlled Biochemi-
cals, Inc., Hopkinton, MA. The following peptide variants were used in
the X-ray crystallographic structural studies described in the subse-
quent sections (Fig. 1): p1-p6WT (RPGNFLQSRP), p1-p6L449F (RPGN
FFQSRP), p1-p6S451N (RPGNFLQNRP), and p1-p6L449F/S451N (RPGN
FFQNRP).
D30N/N88D protease gene construction. The clade B wild-type
(WT) protease gene was constructed synthetically using codons opti-
mized for protein expression in Escherichia coli as previously described,
with the Q7K mutation introduced to prevent autoproteolysis (25). The
D25N mutation was introduced to inactivate the protease and prevent
substrate cleavage, which has previously been shown to have little impact
on the structure of the protease (26); this construct hence will be referred
to asWT throughout. TheD30N andN88Dproteasemutations were then
introduced sequentially into the gene.Mutationswere generated using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and
confirmed by DNA sequencing.
Protein expression and purification. The protease gene was sub-
cloned into the heat-inducible pXC35 expression vector (American Type
Culture Collection [ATCC], Manassas, VA) and transformed into E. coli
TAP-106 cells. Expression and purification of the inactiveWT andD30N/
N88D protease variants were performed as previously described (27). The
protease used in this study was further purified with a Pharmacia Super-
dex 75 fast-performance liquid chromatography (FPLC) column equili-
brated with refolding buffer (50 mM sodium acetate [pH 5.5], 10% glyc-
erol, 5% ethylene glycol, and 5 mM dithiothreitol).
Crystallization and data collection. The crystals used in this study
were obtained under multiple conditions. Protease solutions of between
1.0 and 2.2 mg/ml were equilibrated with a 10-fold molar excess of the
p1-p6 peptide variants, individually, for 1 h on ice. Crystals were grown by
the hanging-drop vapor diffusion method over a reservoir solution con-
sisting of one of the following three buffer solutions: (i) 126 mM sodium
phosphate buffer (pH 6.2), 63 mM sodium citrate, and 20% to 32% am-
monium sulfate; (ii) 0.1 to 0.5 M morpholineethanesulfonic acid (MES)
monohydrate buffer (pH 6.5), 0.1 to 0.4 M ammonium sulfate, and 20 to
31% polyethylene glycol monomethyl ether (PEGMME) 5000; or (iii) 0.1
M citrate (pH 5.5) and 0.5 to 3.0 M ammonium sulfate. X-ray diffraction
data for PRD30N/N88D–p1-p6S451N were collected on the BioCARS beam-
line 14-BMC at the Advanced Photon Source (Argonne National Labora-
tory, Argonne, IL) at a wavelength of 0.9 Å with a Quantum 315 charge-
coupled device (CCD) X-ray detector (Area Detector Systems
Corporation, Poway, CA).Diffraction data for the other 5 complexeswere
collected on the BioCARS beamline 14-IDB at a wavelength of 1.033 Å
with aMar 165CCDX-ray detector (Rayonix, LLC, Evanston, IL). All data
were collected under cryo-cooled conditions.
Structure solution and crystallographic refinement. The data were
indexed and scaled usingHKL-2000 software (HKLResearch, Charlottes-
ville, VA). Structure determination and refinement were carried out using
programs within the CCP4 program suite (28) as previously described
(29). The Matthews coefficient was calculated for all structures to deter-
mine the number of molecules in the asymmetric unit. For complexes
with twomolecules in the asymmetric unit, structure solution was carried
out using the molecular replacement package Phaser (30), whereas for
complexes with one molecule in the asymmetric unit, AMoRe was used
(31). The structure of darunavir (inhibitor) in complex with active pro-
tease was used as the starting model (1T3R) (32). ARP/wARP was used to
build solvent molecules into the electron density (33). Refinement was
carried out using a combination of TLS (34) and restrained refinement
using Refmac5 (35). Each cycle of refinement was followed by model
building and real-space refinement performed using COOT, a molecular
graphics software (36). For all complexes, the peptides were built into the
Fo Fc electron density after two rounds of refinement cycles. The work-
ing R (Rwork) and its cross validation (Rfree) were monitored throughout
refinement. The quality of the structures was assessed using MolProbity
(37).
Analysis of PR–p1-p6 complex structures. Structures of the com-
plexes were compared by superposition of C atoms of the active site
(residues 24 to 26) and the terminal regions (residues 85 to 90) from both
monomers onto a previously solved structure of WT protease in complex
with WT p1-p6 (PRWT–p1-p6WT) (PDB 1KJF) (8). The structure of
PRD30N/N88D–p1-p6L449F could not be obtained by crystallization and
therefore was modeled in silico starting from the PRD30N/N88D–p1-p1WT
structure as a template.On this template, the L449 side chainwas removed
and the position of a Phe side chain was predicted using Prime (38). After
side chain replacement, the structural model was refined by energy min-
imization with the Impref program implemented in Maestro (39). Struc-
tures were visualized using PyMOL molecular graphics software (40). In
crystals with two molecules in the asymmetric unit (Table 1), structural
differences between the two molecules were visualized by distance differ-
ence plots, as described previously (29). In all such cases, these plots indi-
cate minor differences between the two molecules (data not shown), and
the calculated root mean square deviations (RMSDs) range between 0.14
and 0.19 Å (for the entire protease) and between 0.11 and 0.16 Å (for the
p1-p6 peptide). Therefore, in the subsequent structural analyses, only one
molecule from the asymmetric units was chosen based on (i) the unam-
biguous location of side chains for Gag residues 445 to 452 within the
electron density and (ii) lower temperature factors for the p1-p6 sub-
strate.
Determination of hydrogen bonds. Hydrogen bonds were deter-
mined using Maestro (39). A hydrogen bond is defined by a distance of
less than 3.5 Å between donor and acceptor atoms and a donor-hydrogen-
acceptor angle greater than 120° and less than 180°.
Estimation of vdW potential. Interactions between protease and the
p1-p6 peptide were computed as described previously (41) using a sim-
Kolli et al.
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plified Lennard-Jones potential, V(r), with the relation 4ε[(/r)12  (/
r)6], where r is the protease–p1-p6 interatomic distance and ε and  are
the depth of the potential well and the collision diameter, respectively, for
each protease-substrate atom pair. V(r) is computed for all possible pro-
tease–p1-p6 atom pairs within 6.0 Å, and potentials for nonbonded pairs
separated less than a distance at the minimum of the potential were
equated to ε. Using this simplified potential for each nonbonded pro-
tease–p1-p6 atom pair, the total van der Waals (vdW) contact energy,
V(r), was then computed for each protease and p1-p6 residue. Only
residues 445 to 452 of the p1-p6 substrate variants were analyzed, as the
substrate residues beyond these positions are not located within the bind-
ing site.
Calculation of Vin and Vout. The substrate envelope was previously
calculated using a three-dimensional grid-based approach as described
earlier (41). The available crystal structures of the wild-type substrates
(MA-CA, CA-p2, p2-NC, NC-p1, p1-p6, RT-RH, and RH-IN, with PDB
accession codes 1KJ4, 1F7A, 1KJ7, 1TSU, 1KJF, 1KJG, and 1KJH, respec-
tively) were aligned on the WT protease bound to CA-p2 (1F7A) (42)
using C atoms of residues 24 to 26 and 85 to 90 with PyMOL. A grid was
placed on the active site of the protease, and each grid cell was assigned an
initial occupancy of zero. Whenever a grid cell was within the van der
Waals volume of any substrate atom, the occupancy of the grid cell was
increased by one. The grid occupancywas normalized by the total number
of crystal structures after all thewild-type substrate volumesweremapped
onto the grid. The fit of a substrate within this substrate envelope for a
given PR complex structure was then evaluated by Vin and Vout (volumes
of the substrate within and outside the substrate envelope, respectively),
as described in detail elsewhere (41). Only the P4 to P4= regions of the
substrates were analyzed, as the substrate residues beyond these positions
do not have a significant consensus volume. The Vin and Vout for the
p1-p6 variants from all the complexes were compared to those for theWT
complex to estimate their fit within the substrate envelope.
RESULTS
The four p1-p6 substrate variant peptides (WT, L449F, S451N,
and L449F/S451N) were crystallized in complex with WT and
NFV-resistantD30N/N88DHIV-1 protease (Fig. 1). Although the
simultaneous occurrence of L449F and S451Nmutations is infre-
quent (15), the doublemutant was included in this study to inves-
FIG 1 Overall backbone structures of the coevolved andmutant complexes are similar to that of PRWT–p1-p6WT. (A) Superposition of theWT andD30N/N88D
PRs in complex with p1-p6 variants. (B) Superposition of the p1-p6 peptide in the active site of the PR variants. Note the different orientations of theGag452 side
chain. (C) The different p1-p6 peptides used in this study with their Gag numbering as well as the peptide site numbering.
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tigate why the individually favored mutations do not cooccur and
to better understand p1-p6 coevolution. Crystal structures were
solved for all complexes (with the exception of PRD30N/N88D–p1-
p6L449F, whose structure was modeled [see Materials and Meth-
ods]) to a resolution of between 1.6 and 1.9 Å (Table 1). The
structures were analyzed to reveal the changes in protease-sub-
strate interactions and fit within the substrate envelope as a result
of protease resistance and substrate coevolution mutations.
Overall structure of the complexes. The overall structures of
all six complexes are similar to the previously solved PRWT–p1-
p6WT structure, with RMSDs of 0.10 to 0.26 Å for C atoms (Fig.
1A). The protease complexes display the most pronounced back-
bone shifts in the flap-hinge region (residues 35 to 43) and at the
20s loop (RMSDs of 0.36 of 0.40 Å). These changes correlate with
the known flexibility of these loop regions and changes in crystal-
lographic space groups (Table 1). Despite theseminor differences,
the backbones of the complexes superpose very well with the WT
structure (Fig. 1A).
For all structures used in the analyses, including the previously
solved PRWT–p1-p6WT, at least 8 substrate residues that are im-
portant for binding, Gag 445 to 452, are unambiguously located
within the electron density map. All the p1-p6 substrate peptides
are bound to the protease in the same extended conformation as
shown in previous studies (8, 42). The mutant p1-p6 peptides
differ from the PRWT–p1-p6WT structure in that the side chain for
Gag R452 is significantly reoriented, although the side chains of
Gag residues 447 through 451 are relatively unchanged (Fig. 1B).
Despite high overall similarity of the backbone, the structures dis-
play additional subtle rearrangements within the active site.
Hydrogenbonds betweenPRandp1-p6 are compensated for
inmutant complexes.The structures of theWT andD30N/N88D
PR complexes with p1-p6 variants contain an extensive network
of hydrogen bonds between PR and the p1-p6 peptide, both back-
bone to backbone and side chain to side chain, which plays a key
role in substrate recognition and cleavage. Backbone-to-backbone
PR–p1-p6 hydrogen bonds are conserved across all structures in
this study as in WT PR complexes with other substrate peptides
(Table 2) (8). Similarly, five water molecules, including three that
bridge the peptide to the protease, are also conserved across all six
structures.
The most significant change in hydrogen bonds is observed
around residue PR 30b due to a mutation either at residue 30 in
the PR or at the p1-p6 substrate compared to the PRWT–p1-p6WT
structure. In the PRWT–p1-p6WT structure, D30b hydrogen bonds
with the side chains of Gag Q450 and R452 (Fig. 2). In all other
complexes analyzed, the residue 30b hydrogen bond with Q450 is
conserved but the one with Gag R452 is lost due to the altered
orientation of the latter. Instead, Gag R452makes a new hydrogen
bond as the backbone N moves closer to PR D29b (Table 2). This
change is asymmetric and does not involve the other monomer of
the protease, which does notmake hydrogen bonds at positions 29
and 30with the p1-p6 peptide. Therefore, the hydrogen bondwith
D30b lost due to the mutations in either PR or the substrate ap-
pears to be compensated for by enhanced interactions with D29b.
Packing around themutant substrate is enhanced in all com-
plex structures. Packing within the active site was evaluated by
analyzing the vdW interactions between the PR and the substrate,
which are a key component for substrate recognition and cleavage
by the protease. The total vdW interaction energies relative to
those of theWTcomplex are allmore favorable (more negative) in
the mutant complexes (Fig. 3A). Notably, the PR resistance mu-
tations D30N/N88D alone do not significantly change the total
TABLE 1 Crystallographic statistics for the PR–p1-p6 complexes
Parameter
Value for:
PRWT–p1-
p6WT
a
PRD30N/N88D–
p1-p6WT
PRWT–p1-
p6L449F
PRWT–p1-
p6S451N
PRD30N/N88D–
p1-p6S451N
PRWT–p1-
p6L449F/S451N
PRD30N/N88D–
p1-p6L449F/S451N
PDB code 1KJF 4OBG 4OBH 4OBJ 4OBF 4OBK 4OBD
Data collection
Space group P212121 P21 P21 P212121 P21 P212121 P21
a (Å) 51.29 51.67 51.14 51.19 51.55 50.94 51.47
b (Å) 59.07 60.11 62.79 58.3 60.07 58.41 59.54
c (Å) 61.81 60.2 61.46 61.36 60.23 61.46 59.36
b angle 90 99.09 98.03 90 99.25 90 98.6
Z 4 8 8 4 8 4 8
Temp (°C) 80 80 80 80 80 80 80
Resolution (Å) 2 1.78 1.85 1.75 1.68 1.65 1.9
Total no. of reflections 41,786 133,292 113,050 109,140 167,489 155,872 126,355
No. of unique Reflections 12,376 34,288 28,931 14,456 41,265 22,296 32,879
Rmerge (%) 6.7 6.8 7.3 4.5 6.6 8.7 6.4
Completeness (%) 93.4 99.2 99.7 96 99.8 98.1 98.8
Crystallographic refinement
R (%) 20.3 20.04 16.08 14.35 17.97 18.00 20.01
Rfree (%) 25.1 25.46 20.88 18.29 22.89 21.08 24.44
RMSDb
Bond length (Å) 0.006 0.009 0.007 0.009 0.009 0.009 0.009
Bond angle 1.3 1.404 1.554 1.551 1.46 1.589 1.441
a From reference 8.
b RMSD, root mean square deviation
Kolli et al.
7148 jvi.asm.org Journal of Virology
 o
n
 January 11, 2015 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
vdW interaction value, suggesting that the substratemutations are
responsible for enhanced overall packing. WT PR makes more
favorable contacts with the mutant p1-p6 substrates than the
D30N/N88D variant. The total gain in vdW interactions of sub-
strates with the L449F mutation is almost 2-fold larger in D30N/
N88D than in WT protease. In fact, p1-p6 with the L449F muta-
tion is a better substrate for WT enzyme (11, 16).
Although the overall packing around the substrate is more ex-
tensive in the mutant complexes, the vdW contacts are drastically
reduced for protease residue 30b (Fig. 4B), mainly due to an al-
tered orientation of p1-p6 R452 (Fig. 1B and 2; positive values at
P4= position in Fig. 4A). Despite conservation of the hydrogen
bond between PR residue 30b and Gag Q450, the vdW interac-
tions are reduced in the coevolved complexes (positive values at
P2=). However, these losses are compensated for by the increased
interactions of PR D29b (Fig. 4B). The packing around the sub-
strate in this monomer is also rearranged, with interactions lost
with residues 53, 58, 74, and 76 and enhanced with 8, 45, 50, and
87. There are few interactions between D30a and the p1-p6 pep-
tide, and very little change is observed around the othermonomer
due to the D30Nmutation. As a result of this asymmetric interac-
tion between PR and the p1-p6 substrate, compensatory muta-
tions in p1-p6 are clustered from the C terminus to the scissile
bond.
The changes in vdW interactions are also asymmetric for the
substrate around the cleavage site (Fig. 4A). The effect of muta-
tions in either the PR or substrate is not confined to the points of
mutation but instead propagates over all residueswithin the p1-p6
peptide. WT protease packs tighter around the whole core of the
peptide (P3–P3=) in mutant p1-p6 complexes relative toWT sub-
strate, especially at the sites of mutations (Fig. 4A, upper panel,
asterisks). This increase is reflected in the enhanced overall vdW
contacts described above and correlates with more efficient pro-
cessing of mutant p1-p6 by WT protease (11, 16). Although the
TABLE 2 Hydrogen bonds observed in the PR–p1-p6 complexes
p1-p6 atom PR atom
PR
chain
Bond length (Å) in:
PRWT–p1-
p6WT
PRWT–p1-
p6L449F
PRWT–p1-
p6S451N
PRWT–p1-
p6L449F/S451N
PRD30N/N88D–
p1-p6WT
PRD30N/N88D–
p1-p6L449F
PRD30N/N88D–
p1-p6S451N
PRD30N/N88D–p1-
p6L449F/S451N
P445, O R8, NH2 B None 2.7 2.9 2.8 2.7 2.9 None 2.9
G446, N G48, O A 3.0 2.8 3.0 3.1 2.9 3.1 2.9 2.9
G446, O D29, N B 2.8 2.9 2.8 2.8 3.0 2.9 2.8 2.8
N447, N G48, O A 3.0 2.7 2.9 2.9 2.8 2.9 2.9 2.9
F448, N G27, O A 2.9 2.9 2.8 2.8 3.0 3.0 2.8 2.7
F448, O N/D25, ND2 B 2.7 2.7 2.7 2.7 2.9 2.9 2.8 2.8
Q450, N G27, O B 2.9 3.1 3.0 3.0 2.9 3.1 2.9 3.0
Q450, O D29, N B 3.1 3.2 3.1 3.1 3.0 3.3 3.0 3.1
Q450, OE1 D/N30, N B 2.7 2.9 2.7 2.8 2.7 2.9 2.8 2.8
Q450, NE2 N30, OD2 B 3.0 3.0 2.8 2.8 3.0 3.3 3.0 2.9
N/S451, N G48, O A 3.0 2.9 2.8 2.9 2.8 3.0 2.8 3.0
N/S451, O G48, N B 2.8 3.3 3.0 3.0 3.3 3.4 3.3 3.4
S451, OG G48, O B None None None None 3.2 3.0 None None
R452, N D29, OD2 B 3.8a 3.0 3.0 3.0 2.8 3.0 2.8 2.8
R452, NE D30, OD2 B 3.0 None None None None None None None
L/F451, N; N447,
OD1
None None 3.3 3.1 3.1 3.2 3.1 3.5 3.2 3.2
a Length is given for comparison, even though it is longer than the 3.5-Å cutoff criterion.
FIG 2 Altered orientation of p1-p6 R452 and loss of interactions with PR residue 30 in the active site of D30N/N88D protease. Wild-type PR is in gray,
D30N/N88D PR is in pink, and the p1-p6 peptide is in green.
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general trends in repacking around the substrate are similar to
those in the WT protease case, D30N/N88D protease has de-
creased contacts with Gag residue 450 (Fig. 4A, lower panel, P2=)
and has less tightening of the substrate packing, as reflected in the
smaller overall change in vdW energies (Fig. 3A). Interestingly,
despite repacking around the substrate, the enhanced and reduced
contacts almost completely compensate for each other to yield no
considerable overall change in WT substrate vdW interactions
with D30N/N88D protease. Thus, although the per-residue vdW
contacts are altered irrespective of mutations in the PR or the
p1-p6, the overall change in vdW contact potentials of themutant
substrates, and not the WT, are favorable, due to the correlated
changes in interactions between the different substrate sites.
Fit within the substrate envelope is improved by coevolu-
tion. Substrate fit within the substrate envelope for all the mu-
tant complexes was investigated in terms of the volumes that lie
within (Vin) and outside (Vout) the substrate envelope. The
differences in Vin and Vout relative to those for the PRWT–p1-
p6WT structure were computed for all mutant complexes (Fig.
3B and C). The D30N/N99D mutations cause a worse fit of the
WT substrate within the envelope, with a decrease of 58 Å3 in
Vin. The substrate mutations compensated for this loss by al-
most half in the coevolved structures (Fig. 3B).
In all complexes, including the coevolved structures, a muta-
tion(s) either in the PR or p1-p6 reduced Vin (Fig. 3B) and in-
creased Vout (Fig. 3C), suggesting worse fit within the substrate
envelope. However, this apparent overall worse fit is dominated
by changes at the P4= position (Fig. 5B), where the Gag R452 has
rearranged as discussed above (Fig. 1) and protrudes beyond the
substrate envelope. In fact, D30N/N88D protease mutations do
not significantly impact the fit of P3–P3= moieties within the en-
velope, whereas substrate mutations better fill the substrate enve-
lope at the P1= and P3= positions while at the same time causing
protrusions beyond the envelope (positive values with asterisks in
Fig. 5B and C, respectively). The double mutation in the substrate
(L449F/S451N) does not improve the fit within the envelope (Vin)
any further than the individual mutations. Rather, the presence of
the bulky F449 side chain shifts N451 to protrude more outside
the envelope (Vout) (Fig. 5A). This worse fit of the double mutant
(L449F/S451N) within the substrate envelope may be the under-
lying reason why these two mutations do not simultaneously oc-
cur in patient sequences (15), as there is no selective advantage to
substrate recognition to have both changes simultaneously.
DISCUSSION
Drug resistance to HIV-1 PIs reflects a change in molecular rec-
ognition, where a fine balance exists between loss of inhibitor
binding to the PR and substrate recognition and processing of
Gag/GagProPol.When this equilibrium is disturbed, the substrate
sites coevolve and allow the virus tomaintain adequate fitness and
contribute to drug resistance (11, 12, 14, 15). Our analysis of the
crystal structures reveals the molecular basis of p1-p6 substrate
coevolution in response to the D30N/N88D protease mutations
selected under the pressure of NFV inhibition.
The D30N/N88D resistance mutations in protease cause sub-
stantial loss of substrate interactions at residue 30b (Fig. 5 and
Table 2). D30N is one of the few mutations that cause a change in
the charge of an active-site side chain, which disrupts the electro-
static andHbond interactionswithGagR452.D30 is also involved
in an H bond network involving N88 in WT protease (21). The
secondary N88Dmutation restores the net charge of the protease,
as well as causing additional loss of substrate contacts by shifting
residue 30 away from the active site. Coevolution of p1-p6 sub-
strate to include bulkier side chains at Gag positions 449 and 451
enhances substrate packing at the active site, mainly at the muta-
tion sites, but the effects propagate throughout the substrate as
well. Hence, the compensation mechanism for the lost intermo-
lecular interactions due to drug resistance protease mutations is
not simply selecting substrate mutations to restore those interac-
tions through coevolution but also gaining other types of interac-
tions throughout the active site.
FIG 3 Change in mutant structures relative to the wild-type complex (PRWT–
p1-p6WT). (A) Overall vdW interactions between p1-p6 and protease. (B and
C) Vin (B) and Vout (C) for the fit of p1-p6 within the substrate envelope.
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Coevolution mutations also help reinstate the substrate’s fit
within the substrate envelope. The consensus volume occupied by
substrates bound to HIV-1 protease, or the substrate envelope,
defines the substrate recognition motif. We have established that
when inhibitors protrude out of this envelope to contact protease
residues, those sites are selected for primary drug resistance mu-
tations (13). Similarly, we propose that substrates deviating from
the consensus are more susceptible to coevolution with drug re-
sistance mutations (41). The p1-p6 substrate protrudes out the
envelope with aVout higher than expected based on the sequence’s
molecular volume (41), which renders this substrate susceptible to
coevolution. The NFV resistance mutations also cause a decrease
inVin, likely reducing efficiency of p1-p6 recognition and cleavage
and causing the virus to coevolve mutations at this site. In agree-
ment with our previous molecular modeling and dynamics pre-
dictions (24), the crystal structures we present here confirm that
the substrate coevolution compensates for the decrease in Vin due
to protease resistance mutations and optimizes the fit of p1-p6
within the substrate envelope.
The changes in interactions between the different p1-p6 sub-
strate residues and the protease due to mutations are interdepen-
dent and are not simply confined to sites of mutations. The total
vdW interaction potentials of the WT p1-p6 cleavage site with
NFV-resistant D30N/N88D protease are similar to those of the
WT complex. Although the D30N/N88D mutations do not cause
a dramatic change in the total vdW energy, residue 30’s interac-
tions, mainly electrostatic and H bonding interactions with Gag
R452, are substantially reduced. We observed that the R452 side
FIG 4 Changes in vdW contacts between the protease and p1-p6 substrate inmutant complex structures with respect to theWT complex (PRWT–p1-p6WT).WT
and D30N/N88D protease complexes are in upper and lower panels in cool and warm colors, respectively. (A) Change in contacts of substrate p1-p6 residues.
Asterisks below data bars indicate mutation sites. (B) Change in contacts of protease residues. =, residues in monomer b. Significant enhancement in contacts of
protease residue D29b compensates for reduced interactions at residue 30b in all mutant structures.
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chain reoriented from its position in theWT complex and in pre-
vious modeling predictions (43) and shifted toward protease D29
to at least partially compensate for lost favorable electrostatic in-
teractions with residue 30. In the case of coevolution, the larger
side chains introduced by L449F or S451N mutation in the p1-p6
cleavage site increase the overall contacts of the substrate. This
interdependency of interactions at different sites within the p1-p6
cleavage site across complexes with the D30N/N88D PR suggests
that, rather than reinstating the specific lost contact, preserving
the overall interaction potential by coevolution is essential for
recognition and cleavage.
Previously, we showed that L449 and S451 within the p1-p6
cleavage site do not mutate simultaneously (15). Our structures
show that having both mutations at the same time does not offer
any advantages in altering substrate-PR interactions (Hbonds and
vdW contacts) and, furthermore, worsens the fit within the sub-
strate envelope. The overall van der Waals interaction energies of
the double mutant substrate were similar to those with single mu-
tations, and Vin was reduced for D30N/N88D PR. Corresponding
with two large side chains located close to each other, the double
mutant p1-p6 also had a relatively larger Vout that may affect PR
binding and cleavage. Thus, twomutations do not provide any addi-
tional advantage in the context of the D30N/N88D PRmutations, in
agreement with their very infrequent observation together (15).
In our previous study (14) we found that within the p1-p6
cleavage site, L449 and S451, alongwith P453,which is just outside
FIG 5 (A) Fit of p1-p6 substrates into the substrate envelope. (B and C) Change in Vin (B) and Vout (C) in mutant structures with respect to the WT complex
(PRWT–p1-p6WT). WT and D30N/N88D protease complexes are in upper and lower panels in cool and warm colors, respectively. Asterisks above data bars
indicate mutation sites.
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the cleavage site, vary, with a significantly higher rate in the pres-
ence of D30N/N88D (32, 30, and 66%, respectively) than in the
absence of these protease mutations (15, 17, and 30%, respec-
tively). However, unlike with other cleavage site mutations, the
fold change in resistance to nelfinavir was not altered. Although
we might expect the resistant protease to less efficiently cleave the
p1-p6 site and consequently the virus to have reduced fitness in
the absence of these compensatory mutations, we did not observe
a difference in the replicative capacity in patient-derived viral se-
quences in the presence or absence of cleavage site mutations.
However, within these viral strains there are likely other muta-
tions elsewhere either in the protease or in Gag to modulate the
fitness of the virus. Only by engineering these changes into an
otherwise unaltered system can the level of compensation con-
ferred by these coevolving sites be properly assessed.
TheWT p1-p6 cleavage site, in a manner analogous to that for
the NC-p1 cleavage site, may not be the optimum sequence for
efficient cleavage (11), and this suboptimal amino acid sequence
may regulate the sequential processing of Gag (6, 44) in the viral
life cycle. Compared to the WT sequence, the p1-p6 peptide with
the L449F mutation is cleaved more efficiently even by the WT
protease (11, 16). Gag processing by WT protease is enhanced in
the presence of L449F (11, 16, 45, 46). The S451N mutation may
have similar effects on cleavage of the p1-p6 substrate. Similar to
themore efficient processing of Gag A431V at the NC-p1 cleavage
site (24, 27), enhanced contacts with the protease due to bulkier
side chain substitutions by F449 andN451may increase the kinet-
ics of cleavage at the p1-p6 site. Such a more efficient cleavage at
the p1-p6 site by WT PR could affect Gag processing by altering
the relative rate of p1-p6 cleavage and/or by changing the order of
cleavage within Gag. Therefore, the F449 and N451 in the context
of the WT PR would likely be detrimental to this regulated pro-
cessing of Gag and inadvertently affect viral fitness. However, in
the context of the NFV-resistant PR, which is expected to be less
efficient at cleaving the WT p1-p6 junction, these enhanced
contacts with the coevolved p1-p6 substrate improve recognition
and cleavage, which may help restore the correct order of Gag
processing.
Our structural analysis demonstrates that the interactions be-
tween PR and the p1-p6 cleavage site are influenced by mutations
in either the protease or the substrate. The loss of interactions at
one site due to NFV resistance mutations is compensated for by
improved interactions at other sites in a correlated manner. This
interdependency in PR–p1-p6 interactions influences the overall
fit of the substrate within the substrate envelope and is likely to
affect substrate recognition and cleavage in the presence of PR
resistance mutations. Coevolution enables the virus to maintain a
fine balance of substrate recognition and cleavage while avoiding
inhibition by PIs.
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